UBS analyst Andrew Mok maintains Oak Street Health (NYSE:OSH) with a Neutral and lowers the price target from $28 to $21.
FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE (Mirvetuximab Soravtansine-Gynx) in Platinum-Resistant Ovarian Cancer
ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has filed the
